Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.
Also called NCT01624142
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 300 participants
- Sponsor
- Registry
-
NCT01624142 -
2011-005400-15
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Belgium, Brazil, Canada, Czechia, France, Greece, Hong Kong SAR China, Israel, Italy, Japan, Lebanon, Netherlands, New Zealand, South Africa, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01624142. Allocation not applicable; no masking; primary purpose treatment. Start 2012-06-01 (actual); primary completion 2018-05-11 (actual). Results posted on 2019-01-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders
- Acronym
- TAUSSIG
- Condition
- Severe Familial Hypercholesterolemia
- Intervention (Biological)
- Evolocumab
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct01624142- Content hash
96ced22e9437e2551c3d392c02a38ec928061259f08c20c0815c6c3315884994